Laekna, Inc. (HKG:2105)

Market Cap	6.42B +29.5%
Revenue (ttm)	118.76M +20,266.2%
Net Income	-255.19M
EPS	-0.66
Shares Out	418.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,877,000
Average Volume	2,371,625
Open	14.15
Previous Close	14.50
Day's Range	14.15 - 15.79
52-Week Range	8.10 - 23.50
Beta	-1.12
RSI	59.85
Earnings Date	Mar 18, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 84
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2105

Financial Performance

In 2025, Laekna's revenue was 106.72 million, an increase of 20266.22% compared to the previous year's 524,000. Losses were -229.32 million, -9.82% less than in 2024.

Financial numbers in CNY